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Exelixis: Integrated Drug-Discovery and Development
Platform for Human Therapeutics
Perhaps it is not surprising, for a s
company whose name means ‘evo- E
lution’ in Greek, that since its in- s
ception in 1994 Exelixis has grown i
from a primarily genomics-based f
agricultural research venture into a t
drug-discovery and development p
company focused on finding and o
developing new therapies for can- t
cer and metabolic diseases. f
“We were founded in the mid-90’s c
on genetics and genomics research
involving the model systems Dro-
sophila, C. elegans, and zebrafish Ato discover and validate novel
stargets for a variety of disease
states,” explains Michael Morrissey, i
PhD, Senior Vice President of Dis- pcovery. “Starting in 2000, we transi-
ttioned from focusing our efforts on
target discovery and validation to a (
small-molecule drug-discovery par- sadigm with a large library of 4 mil-
lion compounds and critical mass in a
chemistry and pharmacology,” says s
Morrissey. “It became a classic, big
ppharma type of technology platform
while maintaining a very aggressive
biotech environment and culture.”
The 500-person company based Sin South San Francisco, CA was Klaunched in 1994 from the work of
Athree primary founders: Yale Univer-
csity's Dr. Spyridon Artavanis–Tsako-
tnas (now at Harvard University) and
tDrs. Corey Goodman and Gerry Ru-
kbin then at the University of Cali-
ofornia, Berkeley. The team focused
oon model-organism study to eluci-
tdate pathways potentially applica-
wble to human biology. Exelixis was
vconceived as a functional-geno-
Mmics company dedicated to the dis-
Ecovery of novel targets that could
kbe used for drug development.
gYet, before the pharmaceutical
bprogram was up and running, Exe-
glixis focused heavily on genomics-
dbased agricultural research, explains
sCharles Butler, Associate Director
rof Corporate Communications. “It
shas proven to be a great way to le-
sverage our technology platform so
pthat we have the robust pharma-
ceutical pipeline we now have,” he pays. The 30-person agribusiness
xelixis Plant Sciences remains a t
ubsidiary part of the company and d
s based in Portland, Oregon. Speci- t
ically, the plant business involves s
he study of plant genomics and n
lant disease resistance for the aim t
f developing new insecticides. But i
he core of Exelixis’ business is now i
irmly planted on the pharmaceuti- w
al side. tt
w
pt the heart of Exelixis’
t
mall-molecule pipeline n
gs a unique class of com-
pounds—spectrum selec-
d
ive kinase inhibitors a
ySSKIs)—that are neither
celective nor specific for
l
given kinase but in- i
ctead target several im-






t the heart of Exelixis’ small-mole- a
ule pipeline is a unique class of (
herapies involving spectrum-selec- o
ive kinase inhibitors (SSKIs). “The c
inase-inhibitor program is based m
n our fundamental understanding d
f key targets involved in the pa- s
hobiology of cancer and the path- t
ays driving tumor proliferation and e
essel growth (angiogenesis),” says t
orrissey. For the last two years, h
xelixis researchers have taken u
nowledge gained from functional “
enomics and genetics insights to w
undle inhibitory activities into sin- p
le molecules. The company has r
esigned compounds that are not b
elective for just one kinase, Mor- p
issey explains, but are instead t
pectrum-selective in that they s
imultaneously target several im- a
ortant kinases involved in tumor a
roliferation and angiogenesis. IOnce the target kinases are de-
ermined, Exelixis uses the tools of
iscovery and development—high-
hroughput screening, combichem,
tructural biology, comparative ge-
omics, chemoinformatics—to find
he scaffolds and compounds giv-
ng the desired spectrum of activity
n a single molecule. This approach
as initially antithetical to conven-
ional wisdom. “When we started
his effort in 2002, most people
anted to have individual com-
ounds that would be highly selec-
ive, if not specific, for a given ki-
ase,” recalls Morrissey. But tumor
rowth and proliferation in vivo is a
olygenic process; many influences
rive the broad growth and prolifer-
tion of tumors. “We believe that if
ou could pick and choose good
ombinations, you would be more
ikely to have much better efficacy
n both preclinical and, hopefully,
linical testing,” he says.
ancer-Focused Clinical
rograms
xelixis’ lead clinical candidate,
L119 (becatecarin) is not a SSKI
ut a topoisomerase inhibitor char-
cterized by Bristol-Myers Squibb
BMS) and licensed in 2001 as part
f a target-discovery and validation
ollaboration. XL119 is currently in
ultinational phase III trial for bile-
uct tumors. “It has a fairly novel
tructure and is clearly doing more
han just inhibiting topoisomerase,”
xplains Morrissey. BMS charac-
erized this compound in the NCI 60
uman tumor cell line panel often
sed to identify drug sensitivities.
It had a different phenotype than
hat is normally seen with pure to-
oisomerase inhibitors,” says Mor-
issey. The compound has already
een tested in a large number of
atients in the collaboration be-
ween BMS and the NCI, and it has
hown good activity in its phase I
nd II studies. Recruitment for the
nticipated 3-year, 600-patient phase
II study began in mid-2004.
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408In Exelixis’ largest collaboration, i
with Glaxo SmithKline Beecham a
(GSK), it is responsible for discovery P
and development of new drugs for a
cancer, up to proof-of-concept tri- t
als in phase II. The agreement in- d
volves 12 programs that include all a
of Exelixis’ clinical candidates ex- m
cept for XL 119 as well as several c
other preclinical and lead-optimiza- a
tion programs. GSK has the right to
select two to three compounds af- G
ter clinical proof-of-concept has N
been achieved. Exelixis retains the “
rights to the other compounds. n
Two compounds, XL647 and d
XL999, are currently in phase I d
studies, and there are plans to p
move them into phase II in the latter E
half of 2005. They are SSKIs de- e
signed to inhibit a spectrum of re- t
ceptor tyrosine kinases. XL647, an w
orally bioavailable drug, simulta- p
neously inhibits the activity of t
EGFR, HER-2, VEGFR, and EphB4, r
molecules known to facilitate tu- s
mor proliferation and vasculariza- w
tion. XL999 targets FGFR, VEGFR, a
PDGFR—key targets associated with M
development and maintenance of v
tumor vessels—and Flt3. Phase I a
trials with XL999 have included an h
IV form of the drug, although an d
orally bioavailable formulation is i
an option. In preclinical studies, c
XL999 has been shown to induce
t
rapid apoptosis and tumor vascular
t
interruption after just one dose.
m
XL784 is an inhibitor of ADAM-10
kmetalloprotease, known to be in-
svolved in blood-vessel develop-
nment and proliferation. Originally
developed as an anticancer com-
gpound, XL784 has been recharac-
(terized as a therapy for patients
(with diabetic nephropathy because
tof its efficacy in preclinical models
aof renal failure. Phase II trials are
tanticipated for renal disease in
2005. XL 880 just began phase I tri-
cals. “To our knowledge, XL 880 is
dthe most advanced orally active
rsmall-molecule inhibitor of the Met
treceptor tyrosine kinase, one of the
phottest targets in cancer kinase re-
vsearch right now,” says Morrissey,
hwho explains that the inhibitor has
ebeen implicated in virtually all as-
bpects of tumor growth, invasive-
pness, and angiogenesis.
wBehind the compounds involved
tin human clinical programs are
cthree other SSKI compounds,
XL844, XL184, and XL820. XL844 knhibits CHk1 and CHk2. XL 820
cts against VEGFR, KIT, and
DGFR, and XL184 targets VEGFR2
nd Met. “We expect to file INDs in
he first half of 2005 for these
rugs,” says Morrissey. Exelixis
lso has three late-stage lead opti-
ization oncology programs fo-




The technology platform we have
ow is a fine-tuned small-molecule
iscovery engine you can use to
iscover drugs for any target,” ex-
lains Morrissey, explaining why
xelixis is aiming its broad discov-
ry platform to other druggable
argets. “We have done a great job
ith kinases, but it is also very ap-
licable to nuclear hormone recep-
ors (NHRs) and G-protein coupled
eceptors (GPCRs), and we are now
tarting to move into those areas as
ell, with an intent to develop ther-
pies for metabolic disease,” says
orrissey. Known to be ligand-acti-
ated transcription factors, NHRs
re involved in gene expression and
ave an important function in en-
ocrine signaling. They are involved
n a range of metabolic diseases, in-
luding dyslipidemias. GPCRs are
ransmembrane proteins and the
arget of more than half of all phar-
aceutical compounds on the mar-
et today. They are involved in cell
ignaling responses to hormones,
eurotransmitters, and chemokines.
“[We acquired] our NHR pro-
rams focused on Liver X Receptor
LXR) and Farnesoid X Receptor
FXR), and Mineralcorticoid Recep-
or (MR) after the September 2004
cquisition of X-Ceptor Therapeu-
ics,” says Morrissey.
“Nuclear hormone receptors are a
ompletely different class of highly
ruggable targets,” explains Mor-
issey. “They are the classic recep-
ors for steroids that were once or-
han nuclear receptors but are now
ery well known and validated to be
eavily involved in a variety of dis-
ases.” The initial move into meta-
olic disease is an area Exelixis will
ursue vigorously with GPCRs as
ell. Adds Morrissey, “We will have
he ability to go after the three main
lasses of druggable targets—
inases, NHRs, and GPCRs—whichis a good way to marry our powerful
technology platform with the three
of the most successfully drugged
targets in the pharmaceutical in-
dustry.”
Alice A. McCarthy is a freelance sci-
ence writer based in Gloucester,
MA (alice@alicemccarthy.com).
